TWi Pharmaceuticals Inc. pressed the Federal Circuit on Friday to revive its generic version of Takeda Pharmaceutical Co. Ltd.’s acid reflux medicine Dexilant, arguing that Takeda’s patent claims for the drug are invalid in light of a previously issued patent. [Law360]